Ecallantide Injection (Kalbitor)

Elliott, William T.; Chan, James
February 2010
Internal Medicine Alert;2/15/2010, Vol. 32 Issue 3, p21
The article provides information on the indications, dosage and potential advantages and disadvantages of ecallantide, a recombinant protein.


Related Articles

  • Discrepant Results of 2 Screening Tests for Anti-HIV Antibody. Hewlett, Indira K.; Xingxiang Li; Epstein, Jay S. // Clinical Infectious Diseases;9/15/2002, Vol. 35 Issue 6, p773 

    Presents correspondence on discrepancies in the screening for anti-HIV antibody. Use of different arrays of recombinant proteins by drug firms Abbott and Sanofi; Capabilities and limitations of screening assays.

  • Highlights from the March 2009 Issue of DNA and Cell Biology. Handelsman, Jo // DNA & Cell Biology;Mar2009, Vol. 28 Issue 3, p101 

    The article discusses various reports published within the issue, including the method for streamlined and enhanced protein expression in recombinant vaccine viruses developed by Popov and coworkers, and on the functional metagenomics by Allen and colleagues.

  • Untitled. S.E. // Science World;2/25/94, Vol. 50 Issue 10, p5 

    Reports on health news for the month of February in 1994. Use of Kudzu for reducing alcohol craving; Approval of genetically engineered hormone, bovine somatotrophin (BST); Update on cancer drug taxol.

  • The Bush administration deals a blow to biotechnology?and itself. Miller, Henry I. // Nature Biotechnology;Sep2001, Vol. 19 Issue 9, p807 

    Examines federal regulation in the biotechnology sector in the United States. Regulation of recombinant plants; Policy of the Environmental Protection Agency; Occupational exposures to toxic chemicals.

  • Production And Purification Of Recombinant Human Oxytocin Overexpressed As A Hybrid Protein In Escherichia Coli. Roman S. Esipov; Larisa A. Chupova; Sergey V. Shvets; Dmitry V. Chuvikovsky; Alexandr I. Gurevich; Tatyana I. Muravyova; Anatoly I. Miroshnikov // Protein & Peptide Letters;Aug2003, Vol. 10 Issue 4, p404 

    The plasmid DNA pERilox4 containing the gene of the recombinant protein, which included the leader sequence and the oxytocinoyl lysine tetramer, was constructed. The high level of gene expression in E. coli was achieved. The method for purification of the recombinant protein and its isolation in...

  • Molecular biology: Nature of the genetic code finally revealed! van Ooij, Christiaan // Nature Reviews Microbiology;Dec2011, Vol. 9 Issue 12, p835 

    An abstract of the article "General nature of the genetic code for proteins," by F.H.C. Crick and colleagues is presented.

  • Medtronic is asked about unreported effects of spinal drug. Kmietowicz, Zosia // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;7/9/2011, Vol. 343 Issue 7814, p61 

    The article reports on the move of the members of the Senate Committee on Finance to ask Medtronic to provide all communications with medical journals and investigators about the use of morphogenetic protein 2, a recombinant human bone protein that stimulates bone growth.

  • Alefacept. Frampton, James E.; Wagstaff, Antona J. // American Journal of Clinical Dermatology;2003, Vol. 4 Issue 4, p277 

    â–´ Alefacept (recombinant human LFA-3/IgG[sub 1] fusion protein) is a novel biologic agent that selectively targets memory-effector CD45RO+ T lymphocytes, implicated in psoriasis pathogenesis. â–´ In placebo-controlled studies, once-weekly administration of alefacept 7.5mg intravenous...

  • Alefacept: A Viewpoint by Alice Gottlieb. Gottlieb, A // American Journal of Clinical Dermatology;2003, Vol. 4 Issue 4, p287 

    Comments on the use of the recombinant protein Alefacept in the treatment of psoriasis. Background on psoriasis; Features of the recombinant protein; Information on the immunobiological aspect of psoriasis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics